Dexcom has announced a new continuous glucose monitoring system designed for people using basal insulin, oral therapies or GLP-1 receptor agonists1. The new system will be available shortly. Dexcom ...

During Dexcom Investor Day, CEO Jake Leach announced the company's newest CGM monitor, G8, which utilizes technology that ...

Sell in May and Go Away-Starting With These 3 Stocks DexCom (NASDAQ:DXCM) used its 2026 Investor Day to outline a long-range ...

What’s the next CGM step change, and how is Dexcom going to deliver it? That’s one of the fundamental questions Jake Leach has been asked since stepping into the role of CEO at Dexcom. “I want to make ...

Glucose monitoring specialist Dexcom announced it received FDA clearance for its G7 15 Day continuous glucose monitoring (CGM) system for people 18 and older with type 1, type 2 and gestational ...

On the heels of the latest NICE guidelines, Dexcom ONE is in review by NHS England for addition to the Drug Tariff Dexcom ONE, a wearable sensor and transmitter, puts people firmly in control of their ...

Add Yahoo as a preferred source to see more of our stories on Google. (COLORADO SPRINGS) — A medical device for diabetes called the Dexcom is facing a national shortage that’s now leaving diabetics in ...

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (CGM), is happy to share that people with type 1 diabetes who are 25 ...

Dexcom, the locally based maker of continuous glucose monitors for diabetes patients, is projecting billion-dollar growth into 2030, and San Diego stands to profit. The medtech company invested more ...

Dexcom CGM use is proven to improve glycemic control1,2and can reduce the risk of costly diabetes-related complications compared to fingerstick monitoring.3 The Dexcom G6 CGM System is now covered by ...

Although DexCom has significantly underperformed the broader market over the past year, Wall Street analysts continue to ...